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I. Theoretical background and aims of the dissertation 
 
In my thesis I provide analysis of the health economic aspects of chronic urologic 
diseases including benign prostatic hyperplasia, bladder cancer, female and male 
urinary incontinence, lower urinary tract symptoms and overactive bladder syndrome. 
Due to the ageing of the population the prevalence and social burden of these diseases 
increase substantially. These diseases already at present have major cost impacts and 
the related costs are expected to rapidly increase further in the near future. The disease 
incidence within the specified age groups appears to be fairly constant, however due 
to the increasing life expectancy of the population and to the more and more effective 
therapeutic agents, the total number of patients rise significantly.  
The costs rise constantly since these chronic diseases are long-lasting and require 
ongoing medical care. Due to the constantly increasing patient number and social 
burden these issues receive special attention in more and more developed countries.  
Some countries develop “ageing strategies” and health economic research of ageing is 
in the mainstream of health economic research. Substantial data are required in order 
to make adequate health policy decisions and to find sustainable finance solutions.  
Little is known about the epidemiology and social burden of chronic urologic diseases 
in Hungary which makes adequate decision-making in health policy and finance 
remarkably difficult.  
 
In order to come to know the social burden we need to be aware of the epidemiology 
of these diseases including the number of new cases (incidence), the total patient 
number (prevalence), the number of patients in the subgroups important from disease 
severity aspects (since the costs are related to disease severity), the direct and indirect 
costs associated with the disease and the quality of life implications of the disease.  
These pieces of information are necessary in order to assess the real social importance 
of the diseases and to calculate the budget impact and cost-effectiveness of the newer 
and newer and more and more expensive therapies which is an obligation of the social 
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security system and is also essential to develop a sustainable health care finance 
system.  
 
The research published in the thesis includes the health economic evaluation of 
several chronic urologic diseases since we need to compare these results. In order to 
make ranking possible for health policy and financing purposes it is necessary to know 
the number of patients with the diseases concerned, the direct and indirect costs and 
the implications on quality of life and work i.e. the social burden. The aims and the 
hypotheses set for the specific diseases under investigation differed with consideration 
to the characteristics of the field and the available Hungarian and international 
literature, so did the methodology applied differ as well.  
 
The research results published in the thesis previously were not available either in 
Hungary or in the wider region, furthermore we have successfully found and 
published several results for the first time in the literature. The research results fill a 
knowledge gap and can be of use for promoting decision making in health policy and 
finance. 
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I.1 Objectives 
I.1.1 Assessing disease burden and cost of illness in benign prostatic 
hyperplasia 
The detailed objectives of the health economic analysis of benign prostatic hyperplasia 
(BPH) were the following: 
- reviewing and analysing the international and national literature related to social 
burden and cost of illness in benign prostatic hyperplasia   
- assessing cost of illness and quality of life in Hungarian patients diagnosed with 
benign prostatic hyperplasia, undergoing treatment. 
I.1.2 Cost of illness of bladder cancer in Hungary  
Objective of the health economic analysis of bladder cancer patient data: 
- assessing cost of illness in bladder cancer patients, especially the cost of medications  
I.1.3 Female and male urinary incontinence and the epidemiology of lower 
urinary tract symptoms in Hungary 
The objective of our research on male and female urinary incontinence was to study 
the following attributes: 
- studying the epidemiology of female urinary incontinence,  
- studying the epidemiology of male incontinence and the prevalence of lower urinary 
tract symptoms 
I.1.4 Health economic analysis of the treatment of overactive bladder 
syndrome 
In our overactive bladder syndrome (OAB) research we set the following objectives: 
- cost-utility analysis of the treatment of overactive bladder syndrome  
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II. Methodology 
II.1 Assessing social burden, cost of illness and quality of life in benign 
prostatic hyperplasia 
II.1.1 Literature review 
We performed a systematic literature research for the 2005—2015 interval in Medline 
PubMed, which is the most comprehensive medical literature database. Our strategy 
was to search for the free text appearances of terms like cost of illness or cost analysis 
related to benign prostatic hyperplasia in the articles. The following data were 
collected from all included studies: study design, year of publication, geographic 
location, perspective of cost analysis, number of patients, evaluated cost categories, 
year of cost and cost results. 
II.1.2 Cross-sectional questionnaire survey (2014) 
We conducted a non-interventional, multicenter cross-sectional study between June 
and October 2014. Six urology centres participated in the study. Out of patients 
diagnosed with BPH, our study included only those who did not have a prostate 
surgery in their anamnesis. The first part of the questionnaire was completed by the 
patients: this included questions about demography and job, the clinical attributes 
related to the condition of patients, the severity of illness based on self-assessment, 
quality of life questionnaires related to health and questions about availing health 
services 12 months before the filling of the questionnaire. The second part of the 
questionnaire was completed by urology specialists. The filling of this part was done 
partly based on patient documentation in which related data on how long the illness 
has been present and what kind of diagnostic tests and treatments were used were 
present. The questionnaire collected data from the last 12 month before completing the 
survey. 
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We measured the patients’ general, health-related quality of life with the EQ-5D-3L 
questionnaire (hereinafter EQ-5D). For measuring the severity of illnesses, a test for 
the symptoms of prostate diseases (I-PSS) were used. The effect of BPH on work 
productivity was measured with The Work Productivity and Activity Impairment 
(WPAI) questionnaire. Cost calculation was done from a societal perspective 
including medical, direct non-medical and indirect costs in the past 12 months related 
to BPH.  
II.2 Cost of illness of bladder cancer in Hungary 
II.2.1 Analysis of the National Heath Insurance Fund’s drug and patient flow 
database 
For the study of Hungarian bladder cancer patient care international and national 
statistical data along with the National Health Insurance Fund’s drug and patient flow 
database were used. 
II.3 Female and male urinary incontinence and the epidemiology of lower 
urinary tract symptoms in Hungary 
We studied the epidemiology of urinary incontinence with questionnaire survey. 
Anyone could fill out the survey who wanted to participate voluntarily. Questions 
were compiled based on the professional proposal of the Hungarian Society of 
Urology and the Incontinence Patient Association.  
The questionnaire contained 13 questions about urinating habits and the possible 
problems with urinary continence and urination. The study of the Hungarian surgical 
practice of female incontinence and urogenital prolapse was conducted at around the 
same time. The questionnaire was compiled by the leaders of the Hungarian 
Continence Society’s working group. The aim of this was to study Hungarian surgical 
treatments quantitatively and qualitatively. We requested head physicians leading 
Hungarian Urology and Gynaecology Departments to fill the survey titled 
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“Questionnaire about the surgical treatment of female urinary incontinence and genital 
prolapse” in a postal letter between August 2011 and February 2012. 
II.4 Health economic analysis of the treament of overactive bladder syndrome 
The clinical efficacy and cost-utility of solifenacin were studied in overactive bladder 
syndrome. Other medicines also can be given in this indication: currently Detrusitol® 
(tolterodin IR), Ditropan® – Uroxal® (oxybutynin IR) and Emselex® (darifenacin 
CR) are marketed in Hungary. Because of similar indications, we also evaluated the 
cost efficiency of oxybutynin and darifenacin in our study. The objective of our study 
was to compare the effectiveness and costs of different treatment strategies currently 
marketed and financed by social insurance in Hungary. Detrusitol® (containing 
tolterodin) is free-pricing, so we did not include it in our study.  
Cost efficiency analysis was conducted with a decision tree model. Aided by this 
model, we conducted the comparison of the costs and clinical efficacy of solifenacin, 
darifenacin and oxybutynin IR therapies. 
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III. Main results 
III.1 Assessing disease burden and cost of illness in benign prostatic 
hyperplasia 
III.1.1 Literature search 
Literature research yielded 159 matches and we included 11 publications which both 
met the inclusion and exclusion criteria. Four studies were done in European countries 
and seven in The United States. 
Sample size varied between 1000 and 40 253 capita. Nine studies used payer 
perspective for cost calculation, one study used societal perspective and one study 
used both. The time horizon of the studies was between 1 month and 20 years (life 
expectancy of BPH patient at the time of diagnosis); the most commonly used time 
horizon was 1 year. Cost year marked in the studies was between 1998 and 2012. 
direct medical costs of BPH showed a big difference in individual studies. Direct 
annual medical costs per patient fluctuated between 255 USD and 5729 USD in the 
United States, while in Europe, the same costs fluctuated between 253 EUR and 1251 
EUR. In Norway, costs on the 4-year and on the 15.5 year horizon fluctuated between 
1703 and 7638 EUR and 3924 EUR and 8307 EUR respectively, depending on 
treatment modalities and cost calculation perspective. 
The dominant cost drivers were pharmaceuticals since they were accountable for 
nearly three-quarters of the whole treatment cost (the amount of this varied between 
40% in France and 89% in Poland). The costs of surgical treatments were accountable 
for 15% of total cost, while the costs of diagnostic tests were accountable for 8% of 
total cost. More severe illness was accompanied with higher costs both in the cases of 
urination (mild: 673 USD; moderate: 906 UDS; severe: 960 EUR), and in the cases of 
continence symptoms (mild: 623 USD; moderate: 865 EUR; severe: 1043 EUR).  
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Discussion 
In our study, we summarized BPH related cost of illness results of eleven studies 
published in the last 10 years. These studies were conducted in 8 countries of Europe 
and the United States. Direct medical costs per patient fluctuated annually between 
255 USD and 5729 USD in the United States and annually between 253 EUR and 
1251 EUR in Europe. Despite there were no new data available on the nationwide 
expenditures from most countries, the estimated total costs based on per patient results 
were significant in all countries. 
BPH is an age-related illness which is more and more common over the age of 40. 
Due to demographic aging, continually increasing life expectancy and the high 
prevalence of illness, BPH means a high economic burden to the healthcare budget of 
developed countries. Due to demographic factors and the expected novelties in the 
field of urologic surgery, costs of BPH will likely rise in the future.  
 
III.1.2 Cross-sectional survey: cost of illness and quality of life of patients 
diagnosed with benign prostatic hyperplasia 
A total of 246 patients were included in the survey. The average age was 70.6 
(SD=8.1 years), the average duration of the disease was 6.5 years (SD 6.2 years). 
According to the Body Mass Index (BMI), 182 patients (74%) were overweight or 
obese (BMI>25).  
The average of the EQ-5D index and the EQ VAS scores of patients were 0.85 
(SD=0.9) and 68.4 (SD=15.5) respectively. For 111 patients (45%), the EQ-5D index 
was 1. In total, 8%, 19%, 28%, 30% and 31% reported moderate or severe problems in 
self-care, usual activities, anxiety/depression, pain/discomfort and mobility. The 
average of the I-PSS scores was 12.8 (SD=6.3) in the sample. According to the I-PSS 
score, 52 (23%), 136 (61%) and 35 (16%) patients were in the mild, moderate and 
severe BPH groups, respectively. 
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Out of the 246 patients 244 (99%) received outpatient care, and 25 (10%) were 
admitted to hospital because of BPH in the past 12 months. A total of 211 patients 
(86%) were treated with medication, and 35 (14%) were under observation/watchful 
waiting, 7 of whom had indications for surgery. The total annual per-patient cost of 
BPH was 876 € (SD=1829 €).  
The costs broke down as follows: direct medical costs 46%, direct non-medical costs 
31% and indirect costs 23%. Medication costs amounted to 43% of direct costs 
(173€). A major part of the total medication cost (77%) came from fitotherapy (81€) 
and alpha-blockers (55€). In addition, informal care (243€) and visits to private 
medical professionals (132€) also resulted in significant costs. Indirect cost amounted 
to a total of 204 €, where presenteeism was 41% and absenteeism was 59% 
 
There was no significant correlation between the total cost and either age, or the 
duration of the disease or BMI. Age, however, had a positive correlation with direct 
non-medical costs (r=0.268, p<0.001) and was inversely proportionate to indirect costs 
(r=-0.147, p<0.001). No significant correlation was observed between costs and 
catheter use in the research period or between costs and acute urinary retention (AUR) 
in the past 12 months. We found that there was moderately strong correlation between 
the total cost and the I-PSS score (r=0.429, p <0.001). However, there was only weak 
correlation with the EQ-5D index (r = −0.307, p <0.001) and the EQ VAS (r = −0.229, 
p = 0.001). Direct medical costs correlated only with the I-PSS score (r = 0.305, p 
<0.001), while direct non-medical costs correlated with the I-PSS (r= 0.374, p 
<0.001), the EQ-5D (r=−0.416, p <0.001) and the EQ VAS (r = −0.368, p <0.001) as 
well. There was no significant correlation between indirect costs and any of the 
quality of life measures. 
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Figure 1. Average yearly cost per patient by cost category in the I-PSS severity 
groups 
 
 
 
Discussion 
In the present research, we estimated the annual costs of lower urinary tract symptoms 
associated with BPH in Hungary. Cost calculation was conducted from a social 
perspective, and included all direct medical, direct non-medical and indirect costs 
related to BPH. Costs were significantly different in the I-PSS groups. There is a 
considerable cost/patient (approx. 270k HUF). There is a significant number of 
patients, so the social burden is important, and it is important to note that patients bear 
a major part of the costs. 
We were the first in Hungary to publish presenteeism data involving BPH patients - 
this cost element is already significant today and it is going to increase as the 
retirement age increases. 
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III.1.3 Cross-sectional questionnaire survey; quality of life of patients with 
benign prostatic hyperplasia 
At the time of the survey narly half of the patients had urinary problem despite the 
treatment. In the 12 month before the questionnaire was completed, 10% of patients 
were admitted to hospital because of urinary problems (90% of such patients once, 
10% twice), 18% of the patients visited their GP and 76% visited a urologist because 
of the symptoms. A total of 42 patients (17%) were waiting for prostate surgery, 
average age: 70.93 (SD 6.82), the average age of the 194 patients not waiting for 
surgery was 70.39 (SD 8.42) (for 10 patients age was not provided). 
The average of the I-PSS scores was 12.8 (SD=6.3) in the sample. According to the I-
PSS score, 52 (23%), 136 (61%), and 35 (16%) patients were in the mild, moderate 
and severe BPH groups, respectively. 
The average of the EQ-5D index and the EQ VAS scores of patients were 0.85 
(SD=0.19) and 68.4 (SD=15.5) respectively. For 111 patients (45%), the EQ-5D index 
was 1. In total, 7%, 19%, 28%, 30%, and 31% reported moderate or severe problems 
in self-care, usual activities, anxiety/depression, pain/discomfort and mobility. (Figure 
2). Average EQ-5D scores were examined in the I-PSS groups and statistically 
significant differences were found. We have only found significant difference 
(p<0.05) between BPH patients and the age- and sex-matched general population in 
the 45-49 and 55-59 age groups. 
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Figure 2. Comparison of BPH patients and age- and sex-matched general 
population in the 5 dimensions of the EQ-5D questionnaire 
 
 
 
Discussion 
In our study, the clinical characteristics and health-related quality of life were 
examined in BPH patients. We would like to highlight from our results that almost 
50% of patients had urinary problems despite the treatment with medication, most of 
the time urinary frequency and a compelling urge to urinate. The majority of the 
patients in the sample considered their general health good, according to the EQ-5D, 
almost half of the patients (45%) reported no problems in any of the 5 dimensions of 
the questionnaire. The average EQ-5D index of BPH patients in the 45-49 age group 
was lower than that of the sex and age-matched general population, the results were 
the same in the 60-64 age group, while in the 50-54, 55-59 and 65-74 age groups it 
was higher in BPH patients.  
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The average of the EQ-5D index in the whole sample was 0.85 (SD=0.19), which was 
similar to the findings of studies in other countries. The values are the following in the 
various countries: Spain: 0.90, SD=0.14, average age: 63 years (33), France: 0.84, 
SD=0.19, average age: 72 years (34), Korea: 0.85, SD=0.19, average age: 76 years 
(35), and the United Kingdom: 0.71-0.87 depending on severity, average age: 73 years 
(36). International comparison is made difficult by the fact that the BPH quality of life 
studies were partly randomized controlled clinical studies, partly cross-sectional 
studies related to drug trials. The EQ-5D scale were used only in a smaller part of the 
BPH quality of life surveys, and where it was applied, no comparison with the 
population average was provided. Inclusion criteria were also different, so 
international comparison is difficult. 
As the total I-PSS score increased, the value of the EQ-5D index significantly 
decreased, i.e. as the disease became more severe, general quality of life dropped. 
There was significant, but weak correlation between EQ-5D and the I-PSS score, and 
also the I-PSS quality of life scale.  
Based on our results, it can be established that the health related quality of life of BPH 
patients who are treated with medication is, on average, not worse than that of the 
general population, however, in the youngest age group, significantly lower quality of 
life values were established. There was no difference in the 60-64 age group. In the 
45-49 age group, the quality of life of BPH patients was significantly lower than that 
of the general population.  
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III.2 Cost of illness in patients with bladder cancer in Hungary 
 
III.2.1 Cost of illness in bladder cancer patients, analysis of pharmaceutical 
sales data by the OEP, 2008-2014 
 
A study analysing the years 2007 and 2008, published in 2010 (OEP Elemzési, 
Orvosszakértői és Szakmai Ellenőrzési Főosztály - 2010), provides an overview of the 
costs paid by the Országos Egészségbiztosítási Pénztár (OEP) for bladder cancer (ICD 
C67). According to the report, in 2007 the OEP paid 1.8 bn HUF on the treatment of 
bladder cancer (BNO C67) 75% of which was provided to inpatient care. In 2008, 
total costs exceeded 2 bn HUF, 71.5% of which went to inpatient care. Social security 
expenditure in this diagnosis increased by 33%, by more than 100 million HUF, 
between 2007 and 2008 (2007: 314,425 million HUF, 2008: 418,193 HUF million).  
 
In 2008, OEP provided 58.89 billion HUF social security funding for the oncology 
medication of cancer patients.  
We analysed pharmaceutical sales data by OEP for the 2008-2014 period. For the 
analysis, we could only take into account the medicinal products that are paid for by 
the OEP exclusively for the treatment of bladder cancer, based on indication, with 
special reimbursement, to prevent the recurrence of tumour locally, in the bladder. 
However, these constitute only a segment of the therapies that may be used for the 
treatment of the bladder, and do not include the drugs used in systemic chemotherapy, 
painkillers, antibiotics or other medication, and drugs used during hospital treatments. 
 
 
Discussion 
By analysing the pharmaceutical turnover data, it is apparent that costs of treating 
urinary bladder cancer via medication is significant on a national level. Even during a 
one-year interval (2007 vs 2008), it is clear that the medication costs can significantly 
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rise (with more than 33% meaning 100 million HUF between 2007 and 2008). In the 
analysis of the 2008-2014 interval, we have focused on the turnover of mitomycin 
which was the most significant active agent financially in 2008, as well as two other 
products (epirubicin and bcg vaccine) which can only be used with funding only in 
case of this disease and incur significant charges. Due to the changes implemented in 
the social security funding between 2008 and 2014, withdrawals and restrictions, we 
have found radical restructuring in product turnover for all three products. Mitomycin 
expenses have been reduced to zero by 2014, although its 20 mg variation gave 33% 
of the total medication expenses for urinary bladder cancer back in 2008. Meanwhile, 
the turnover of epirubicin increased while the turnover of bcg vaccine significantly 
decreased from 2013. In total, the social security funding of these three active agent 
have been reduced with 112 million HUF between 2008 and 2014 (from 234,5 to 
112,7 million HUF). According to the summarizing analysis of the 2017 European 
clinical policies, mitomycin may decrease the chance of recurrence in certain cases 
which means that the reasons and consequences behind the absence of mitomycin 
turnover in Hungary by 2014 require further investigation. 
 
III.3 Epidemiology of female and male urinary incontinence and lower urinary 
tract symptoms in Hungary 
 
III.3.1 Surgical treatment practice of female urinary incontinence and 
urogenital prolapse in Hungary 
A total of 10 403 women (18 or older) took part in the survey, with the average age of 
43,0 (SD 13,8). In the survey, 3506 (33,9%) women answered regarding the 
incontinence related question that they have experienced leakage - they were included 
in the incontinence subgroup analysis. The average age of the adult female 
incontinence subgroup is 47,0 (SD 12,7). 
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Urine leakage occured rarely (e.g. during a cold) with 3103 (90,4%) women, and 296 
(8,6%) said they experience it more times a day; a total of 33 (1,0%) women said this 
means a constant issue to them. Detailed questions regarding the occurrence of urine 
leakage revealed that urine leaks mostly occur during coughing/sneezing (2437 
women, 69,5% of the incontinent subgroup; 23,7% of all the participants) or in case of 
strong urinary urgency (823 women, 23,5% of the incontinent subgroup; 7,9% of all 
the participants). The amount of leaked urine is only a few drops in case of the 
majority (3172, 94,1%), a bigger amount for 28 women (0,8%), and 170 women 
(8,0%) marked the answer as “flowing”. As to the question of how much they are 
irritated by involuntary urine leakage, 1319 (39,9%) women said sometimes, 1170 
(35,4%) said very much and 33 (1,0%) said they are being restricted in their everyday 
activities. 
 
Discussion 
The Hungarian studies revealed that 90,4% of women (a total of 10403 adult female 
participant, 3506 incontinence and 3103 urine leakage replies) “sometimes” 
experience OAB symptoms. In case we compare it to the results of United Kingdom 
and Sweden, that means that 791-1040 women (25,5-33,5%) are irritated moderately 
and 118-270 are very much irritated by these symptoms. (Projected to 1000 
incontinence patients, 76-100 women are moderately irritated by OAB symptoms, 
while this number is 255-335 women in case of 1000 OAB patients with 
incontinence.) Third of the participants (33,9%) reported that they experienced urine 
leakage, meaning they had an incontinent episode. More than third of the participants 
(41%) reported urinary urgency. It can be assumed of these patients that OAB may be 
in the background.  
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III.3.2 The prevalence of male lower urinary tract symptoms in Hungary 
The average I-PSS score was 4.2 (SD 3.9) in our study. The distribution between mild, 
moderate and severe categories happened accordingly: I-PSS=0–7: 6378 men (86.4%) 
average age was 38.2; I-PSS=8–19: 919 men (12.7%) average age was 46.1; I-
PSS=20–35: 85 men (0.9%) average age was 55.2. 
Most of the participants were in age group 30-39, their average I-PSS score was 3.52. 
They were followed by age group 40-49 with average I-PSS score of 4.01 then age 
group 20-29 with average I-PSS score of 3.26. The number of participants above the 
age of 50 was 1614. Moving on to higher age groups, the participants’ average I-PSS 
score was increasing. We have studied the proportion of participants reporting mild, 
moderate or severe symptoms in each age group.  
Surprisingly, there were some participants who were in age group 20-29 but still got 
an I-PSS score that relates to moderate or severe symptoms (2 men had a score for 
severe and 102 men had a score for moderate symptoms). Most of the participants 
reporting moderate symptoms belonged to age group 50-59 (245 men), whereas most 
of the participants reporting severe symptoms were from age group 50-69 (total of 55 
men). 
 
Discussion 
More surveys have been conducted worldwide within the adult male population in 
order to get a better knowledge on the epidemiologic background of BPH and the 
patients’ urinary symptoms. Our own results show that a smaller proportion of the 
participants reported “rather voiding” symptoms in all the age groups. This ratio 
ranges between 14-28%. The distribution of “rather voiding” and “rather storage” 
related complaints is 38% vs 60% in favor of “rather storage” amongst patients with 
moderate and severe symptoms. The average score was 8.28 with patients above 60, 
which translates to moderate symptoms/complaints and may require medication or 
surgical therapy depending on the nature of the symptoms. One of the deficiencies of 
this study is that the surveys do not provide any data on BMI scores, medical history, 
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medications, any treatments that relate to prostate or bladder, surgeries and other 
important factors.  
 
III.4 Health economic evaluation of the treatment of overactive bladder 
syndrome 
Results and discussion 
We have studied the cost effectiveness and cost efficiency of solifenacin, oxybutynin 
and darifenacin therapies with a decision making tree. The quality-adjusted life years 
are very similar for all of these active agents. The total costs during a three-month 
interval, is different for each type of therapy based on the distribution of medication 
costs and other costs. The lowest of the total costs is for oxybutynin (19 687 HUF), 
but the medication costs constitute only the 29%. The same rate for darifenacin and 
solifenacin is significantly higher, more than 70%. The related costs of darifenacin 
and solifenacin therapy are almost the same (41 674 HUF, 41 749 HUF). However, 
the highest QALY of the three therapies belongs to solifenacin (0.17486 QALY). 
Even though there are some cost efficiency studies available for these active agents, 
those cannot be directly compared to our results due to the different utility 
measurements used.  
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